Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston May 28, 2020 4:07am
217 Views
Post# 31081551

RE:RE:RE:RE:RE:RE:Uplisting to Nsadaq!!!

RE:RE:RE:RE:RE:RE:Uplisting to Nsadaq!!!
Kusanation wrote: That is not even relative at this point though because they are not on NASDAQ. So hypothetically speaking, let's say the news comes back negative (which I highly doubt it will) or there is more delays (which I personally doubt as well) they wouldn't risk being delisted from NASDAQ as they arnt even on that exchange ? Companies do reverse splits when they are already on NASDAQ and have a share price under $1 USD for over 30 days. The reserve split would make their share price higher by number bust the value of each share would still be relative to what it was before. I can't see this going anywhere near $1 after the announcement as it will be well above IMO. Especially after a a buyer comes in and news of the up listing. I'd be holding this until the end of the year at least. Too many big moves coming from now until then to release your stock. Now is the time to hold and collect folks! GL! 


Generally two guidelines (in my view) for junior companies doing reverse splits when listing on major US exchanges. 1. to attain and maintain minimum Exchange  share price requirements(e.g $1 for x days) as Mano said,  2. To attract institutional investors, many who are precluded from, or choose not to, invest  in companies  with share prices less than $5.  If Antibe goes down this route, I suspect they will choose a reverse split ratio that gives then some breathing room above the $5 floor for institutional investors , but below a level which will still attracts speculators  ($7-$10.).


Bullboard Posts